Ana Garção
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Garção has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Anabela Rodrigues
Serviço de Imuno-Hemoterapia, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal
2 shared publications Alfonso Rodriguez Gil
Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Rocío, Junta de Andalucía, Consejo Superior de Investigaciones Científicas), Seville, Spain
1 shared publication- Ana Cláudia Ribeiro
João Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal
1 shared publication - Ana Cristina Alho
JLacerda Lab, Hematology and Transplantation Immunology, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
1 shared publication Ana Miguel Quintas
10Serviço de Oftalmologia, Hospital de Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal
1 shared publication- Ana Rita Rodrigues
Clinica Universitária de Medicina Intensiva, FMUL, Lisbon, Portugal; Intensive Care Department, Hospital St(a) Maria, Lisbon, Portugal
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 2904-2915
Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease
Chronic graft-versus-host disease (cGVHD) remains a major hurdle to the success of hematopoietic stem cell transplantation, directly affecting patient morbidity and mortality. Impaired regulatory T-cell (Treg) recovery in patients with cGVHD has led to clinical studies aiming to increase peripheral Treg numbers. We conducted phase 1 dose-escalation clinical trials testing the feasibility and safety of using freshly isolated donor-derived Treg infusions in steroid-refractory/dependent cGVHD. The phase 1 was extended to a preliminary phase 2 trial, resulting in a total of 33 treated patients. We report that Treg purification from donor leukapheresis using CliniMACS were feasible and that Treg infusions were safe. Importantly, Treg infusions resulted in improved symptoms, particularly at higher Treg doses. Global responses were observed in 71% of patients, and 52% of patients had at least a 2-point improvement in the cGVHD severity scale. Furthermore, improvement in cGVHD symptoms resulted in reductions in corticosteroids, ruxolitinib, and mycophenolate in 58%, 83%, and 33% of patients, respectively, whereas calcineurin inhibitors were discontinued in 75% of patients. Exploratory analyses revealed the detection of infused Treg clonotypes up to 12 months after infusion and suggest increased Treg numbers in circulation. We observed increases in serum levels of interleukin-7 and interferon gamma and decreases in soluble CD13 and suppression of tumorigenicity 2 over time, which were not statistically significant after adjustment for multiple comparisons. Although these studies were not powered to assess efficacy, they suggest potential therapeutic benefits of donor-derived Treg in cGVHD treatment and highlight the need for larger phase 2 clinical trials. The trials were registered at www.clinicaltrials.gov as #NCT02385019 and #NCT03683498.
- 29 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (9) , 2904-2915
Open AccessPhase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease
Chronic graft-versus-host disease (cGVHD) remains a major hurdle to the success of hematopoietic stem cell transplantation, directly affecting patient morbidity and mortality. Impaired regulatory T-cell (Treg) recovery in patients with cGVHD has led to clinical studies aiming to increase peripheral Treg numbers. We conducted phase 1 dose-escalation clinical trials testing the feasibility and safety of using freshly isolated donor-derived Treg infusions in steroid-refractory/dependent cGVHD. The phase 1 was extended to a preliminary phase 2 trial, resulting in a total of 33 treated patients. We report that Treg purification from donor leukapheresis using CliniMACS were feasible and that Treg infusions were safe. Importantly, Treg infusions resulted in improved symptoms, particularly at higher Treg doses. Global responses were observed in 71% of patients, and 52% of patients had at least a 2-point improvement in the cGVHD severity scale. Furthermore, improvement in cGVHD symptoms resulted in reductions in corticosteroids, ruxolitinib, and mycophenolate in 58%, 83%, and 33% of patients, respectively, whereas calcineurin inhibitors were discontinued in 75% of patients. Exploratory analyses revealed the detection of infused Treg clonotypes up to 12 months after infusion and suggest increased Treg numbers in circulation. We observed increases in serum levels of interleukin-7 and interferon gamma and decreases in soluble CD13 and suppression of tumorigenicity 2 over time, which were not statistically significant after adjustment for multiple comparisons. Although these studies were not powered to assess efficacy, they suggest potential therapeutic benefits of donor-derived Treg in cGVHD treatment and highlight the need for larger phase 2 clinical trials. The trials were registered at www.clinicaltrials.gov as #NCT02385019 and #NCT03683498.
- Open Access
- 3 July 2023
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 36 (7-8) , 496-505
COVID-19-associated Coagulopathy Characterization using Rotational Thromboelastometry in a Prospective, Observational Cohort Study: The HemoCoV Study
Introduction: COVID-19-associated coagulopathy includes systemic and endothelial inflammation with coagulation dysregulation related to immunothrombosis. The aim of this study was to characterize this complication of SARS-CoV-2 infection in patients with moderate to severe COVID-19. Methods: An open-label, prospective observational study conducted in patients with COVID-19 moderate to severe acute respiratory failure admitted to an intensive care unit (ICU). Coagulation testing, including thromboelastometry, biochemical analysis and clinical variables, were collected at prespecified time points during the 30 days of ICU stay.Results: The study included 145 patients, 73.8% male, with a median age of 68 years (interquartile range - IQR 55 - 74). The most prevalent comorbidities were arterial hypertension (63.4%), obesity (44.1%) and diabetes (22.1%). Simplified acute physiology score II (SAPS II) was on average 43.5 (11 - 105) and sequential organ failure assessment (SOFA) at admission was 7.5 (0 - 14). During ICU stay, 66.9% of patients underwent invasive mechanical ventilation and 18.4% extracorporeal membrane oxygenation support; thrombotic and hemorrhagic events occurred in 22.1% and 15.1% of the patients respectively; anticoagulation with heparin was present in 99.2% of patients since early ICU stay. Death occurred in 35% of patients. Longitudinal studies revealed changes in almost all coagulation tests during the ICU stay. SOFA score, lymphocyte counts, some biochemical, inflammatory and coagulation parameters, including hypercoagulability and hypofibrinolysis seen in thromboelastometry, differed significantly (p < 0.05), between ICU admission and discharge. Hypercoagulability and hypofibrinolysis persisted throughout ICU hospitalization, showing higher incidence and severity in non-survivors.Conclusion: COVID-19-associated coagulopathy is characterized by hypercoagulability and hypofibrinolysis from ICU admission, and persisted throughout the clinical course in severe COVID-19. These changes were more pronounced in patients with higher disease burden and in non-survivors.
- 3 July 2023
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 36 (7-8) , 496-505
Open AccessCOVID-19-associated Coagulopathy Characterization using Rotational Thromboelastometry in a Prospective, Observational Cohort Study: The HemoCoV Study
Introduction: COVID-19-associated coagulopathy includes systemic and endothelial inflammation with coagulation dysregulation related to immunothrombosis. The aim of this study was to characterize this complication of SARS-CoV-2 infection in patients with moderate to severe COVID-19. Methods: An open-label, prospective observational study conducted in patients with COVID-19 moderate to severe acute respiratory failure admitted to an intensive care unit (ICU). Coagulation testing, including thromboelastometry, biochemical analysis and clinical variables, were collected at prespecified time points during the 30 days of ICU stay.Results: The study included 145 patients, 73.8% male, with a median age of 68 years (interquartile range - IQR 55 - 74). The most prevalent comorbidities were arterial hypertension (63.4%), obesity (44.1%) and diabetes (22.1%). Simplified acute physiology score II (SAPS II) was on average 43.5 (11 - 105) and sequential organ failure assessment (SOFA) at admission was 7.5 (0 - 14). During ICU stay, 66.9% of patients underwent invasive mechanical ventilation and 18.4% extracorporeal membrane oxygenation support; thrombotic and hemorrhagic events occurred in 22.1% and 15.1% of the patients respectively; anticoagulation with heparin was present in 99.2% of patients since early ICU stay. Death occurred in 35% of patients. Longitudinal studies revealed changes in almost all coagulation tests during the ICU stay. SOFA score, lymphocyte counts, some biochemical, inflammatory and coagulation parameters, including hypercoagulability and hypofibrinolysis seen in thromboelastometry, differed significantly (p < 0.05), between ICU admission and discharge. Hypercoagulability and hypofibrinolysis persisted throughout ICU hospitalization, showing higher incidence and severity in non-survivors.Conclusion: COVID-19-associated coagulopathy is characterized by hypercoagulability and hypofibrinolysis from ICU admission, and persisted throughout the clinical course in severe COVID-19. These changes were more pronounced in patients with higher disease burden and in non-survivors.